Raw Material Nitrofurantoin for Antibiotics (CAS 67-20-9)

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Yellow Powder
• Purity: >99%
• Model NO.: Frazer-Nitrofurantoin
• Appearance: Yellow Powder
• CAS No: 67-20-9
• Shelf Life: 2 Years
• Test Method: HPLC
• MOQ: 1kg
• Storage: Store Cool Dry Place
• Resource: Natural
• Quality Requirement: Strictly Quality Control
• Service: Good Service
• Transport Package: Foil Bag
• Specification: 99%
• Trademark: Xi′an Frazer Biotech Co., Ltd.
• Origin: China
• Production Capacity: 2000kg/Month

Product Description

Raw Material Nitrofurantoin for Antibiotics (CAS 67-20-9)

Specification of Analysis

Description	Yellow powder	Complies
Identification	IR	Complies
Test	HPLC	Complies
Heavy metal	≤10ppm	5ppm
Pb	≤3ppm	1.5ppm
Hg	≤0.1ppm	0.05ppm
Cd	≤1ppm	0.2ppm
Loss on drying	≤0.5%	0.12
Residue on lgnition	≤0.1%	0.03
Single impurity	≤0.5%	0.12
Total impurity	≤1.0%	0.29
Total bacteria	≤1000cfu/g	<1000
Yeast and Mould	≤100 cfu/g	<000
E.coli/25g	Absent	Absent
Salmonella/25g	Absent	Absent
Assay	≥99.0%	99.4%
Conclusion	Conforms with USP/EP standards

 

Product description:
 

Nitrofurantoin, sold under the trade name Macrobid among others, is an antibiotic used to treat bladder infections.It is not effective for kidney infections. It is taken by mouth. Common side effects include nausea, loss of appetite, diarrhea, and headaches. Rarely numbness, lung problems, or liver problems may occur. It should not be used in people with kidney problems.While it looks like it is generally safe during pregnancy it should not be used near delivery.It works by slowing growth rather than killing bacteria.

Function & Application:

Nitrofurantoin has been available for the treatment of urinary tract infections (UTIs) since 1953. Its currentuses include the treatment of uncomplicated UTIs and prophylaxis against UTIs in people prone to recurrent UTIs.

Increasing bacterial antibiotic resistance to other commonly used agents, such as fluoroquinolones and trimethoprim/sulfamethoxazole, has led to increased interest in using nitrofurantoin.Several trials comparing nitrofurantoin to other commonly used agents have shown this drug results in similar cure rates for uncomplicated UTIs.The efficacy of nitrofurantoin in treating UTIs combined with a low rate of bacterial resistance to this agent makes it one of the first-line agents for treating uncomplicated UTIs as recommended by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.Nitrofurantoin is not recommended for the treatment ofpyelonephritis,prostatitis and intra-abdominal abscess,because of extremely poor tissue penetration and low blood levels.